A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Savolitinib (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca; Hutchison MediPharma
  • Most Recent Events

    • 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in Q1 2012.
    • 31 May 2016 Status changed from recruiting to completed.
    • 22 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top